Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Columbia University Department of Medicine, Division of Cardiology, New York, New York, USA.
Am J Hypertens. 2016 Nov 1;29(11):1276-1282. doi: 10.1093/ajh/hpv172.
There are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI-ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM.
We analyzed data from the ACCORD BP trial-a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI.
Data from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance.
In patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM. clinical trials registration Trial Number NCT00000620.
目前尚无明确策略可用于预防 2 型糖尿病(T2DM)患者的心房颤动(AF)。我们比较了标准降压与强化降压在降低 T2DM 患者 AF 或 P 波指数(PWI-ECG 左房异常的标志物,被认为是 AF 的中间表型)发生率方面的效果。
我们分析了 ACCORD BP 试验的数据——这是一项随机对照非盲试验(2001-2009 年),纳入了年龄在 40-79 岁且伴有心血管疾病(CVD)或年龄在 55-79 岁且伴有亚临床 CVD 或有≥2 个 CVD 危险因素的正在接受≤3 种降压药物治疗且收缩压(SBP)为 130-180mmHg 的 T2DM 患者,将其随机分为标准降压组(SBP<140mmHg)与强化降压组(SBP<120mmHg)。主要结局为 AF 与 PWI 的复合终点。
共纳入了 3087 名参与者(平均年龄 62.2 岁;女性 48.2%;非白人 39.2%),平均随访 4.4 年后,1063 名参与者(标准治疗组发生率为 84.5/1000 人年,强化治疗组发生率为 73.9/1000 人年)发生了主要结局。强化治疗组的主要结局及单独发生 PWI 的调整后风险比(95%置信区间)分别为 0.87(0.77-0.98),P=0.02 和 0.87(0.76-0.98),P=0.02。强化治疗对 AF 发生率的影响未达到统计学意义。
在 T2DM 患者中,强化降压可降低 AF 与 PWI 复合终点的发生率,提示严格血压控制可能对 T2DM 患者有益。临床试验注册号 NCT00000620。